Reactions 1664, p3 - 12 Aug 2017
Risk of kidney disease with
The risk of chronic kidney disease (CKD) is now
included in the product information for two atazanavir-
containing medicines in Canada.
In the July issue of Health Product InfoWatch, it was
reported that this risk had been included in the Canadian
Product Monographs (CPMs) for atazanavir/cobicistat
(Evotaz) and atazanavir alone (Reyataz).
Specifically, the ’Warnings and Precautions’ and
’Adverse Reactions’ sections of the CPMs for these
products will include the following key messages for
CKD has been reported in patients treated with
atazanavir (± ritonavir). Some cases resulted in fatal
outcomes or requiring haemodialysis.
Evotaz and Reyataz should be used with caution,
especially in patients with other risk factors for CKD.
Health Canada. Evotaz (atazanavir and cobicistat) and Reyataz (atazanavir). Health
Product InfoWatch : 7, Jul 2017. Available from: URL: https://www.canada.ca/
Reactions 12 Aug 2017 No. 16640114-9954/17/1664-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved